CGRP Forum
Send to a colleague
Register  Login
Home   |   About   |   About CGRP   |   News   |   Hot Topics   |   Trials    |   Resources   |   Contact

New video: CGRP in cluster headache

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Watch the video here »

New Hot Topic: Anti-CGRP therapy in Japan – progress and expectations

CGRP-based therapy is not expected to be approved in Japan until 2021, but clinical trial data have been reported on three agents and there is a high level of expectation amongst Japanese clinicians – as Mamoru Shibata, Associate Professor in the Department of Neurology at Keio University School of Medicine, Tokyo, explains.

Read more here »

Ajovy (fremanezumab) prescription agreed for migraine prophylaxis in Scotland

Ajovy (fremanezumab) can be prescribed on the National Health Service (NHS) in Scotland for patients with chronic or episodic migraine who have failed on three or more preventive treatments, following a decision from the Scottish Medicines Commission (SMC).

Read more here »

Vazegepant shows efficacy in acute migraine treatment

Intranasal vazegepant 10 and 20 mg doses were statistically superior to placebo in achieving freedom from pain and the most bothersome symptom two hours after administration, according to results of a dose ranging Phase 2/3 study in 1,673 patients with acute migraine.

Read more here »

For all the other recent migraine news featured on the CGRP Forum click here »

Becoming a member is easy

Members have free open access simply by registering online.
Facebook Like us on Facebook
For the latest updates, CGRP news and analysis.
Twitter Follow us on Twitter
Hot topics, news and conference reports.
Educational Partners and Supporters (others pending) Logos
© Copyright CGRP Forum 2020. Please click here to unsubscribe from future mailings.